| Literature DB >> 30733762 |
Md Anowar Khasru Parvez1,2, Rabeya Nahar Ferdous1, Md Shahedur Rahman3, Sohidul Islam4.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) has long been a common pathogen in healthcare facilities, but now, it has emerged as a problematic pathogen in the community setting as well. This study reported source, diagnosis and treatment of HA-MRSA and CA-MRSA. A total of sixty-five clinical samples (urine, pus, wound swab) were collected from clinical origin of Dhaka city, Bangladesh. All the isolates were tested phenotypically by conventional methods and genotypically by PCR targeting nuc, pvl and mecA genes. Finally sequencing was carried out for pvl gene to know the mutagenic variation or any amino acid changes in pvl gene. Chi square test was employed for statistical analysis. Patients of age group 51-60 years are more susceptible (46.15%) to MRSA, CA-MRSA or HA-MRSA infection. Female are (32.30%) more susceptible to MRSA infection. Among 65 isolates 53 isolates identified phenotypically as S. aureus. These were positive for amplification of nuc (270 bp) gene of S. aureus. Moreover, among 53 isolates 33 phenotypically considered as MRSA and 38 (72%) showed positive amplification for mecA (162 bp) gene. Among 38 MRSA isolates 22 (57.89%) confirmed as CA-MRSA and 16 (42.10%) as HA-MRSA. Finally, sequence analysis for lukS/F-PV genes from 4 representative isolates detected a new single nucleotide polymorphism in comparison with the control sequence. However, no amino acid changes were found. Statistical analysis showed HA-MRSA isolates were more commonly found in urine sample and CA-MRSA in pus and wound swab. CA-MRSA isolates were more resistant to tested antibiotics than HA-MRSA.Entities:
Keywords: CA-MRSA; HA-MRSA; MRSA; Nuc gene; PCR; Pvl gene; S. aureus; mecA gene
Year: 2018 PMID: 30733762 PMCID: PMC6353753 DOI: 10.1016/j.jgeb.2018.05.004
Source DB: PubMed Journal: J Genet Eng Biotechnol ISSN: 1687-157X
Sample size and type.
| Sample size (No. of samples collected) | Sample type (urine, pus, wound swab) |
|---|---|
| 36 | Urine |
| 18 | Pus |
| 11 | Wound swab (w/s) |
PCR thermocycling conditions.
| Gene | Temperature (°C)/time cycle | Cycle No. | ||||
|---|---|---|---|---|---|---|
| Initial denaturation | Cycling condition | Final extension | ||||
| Denaturation | Annealing | Extension | ||||
| 95/10 min | 94/1 min | 55/30 sec | 72/1.30 sec | 72/3.30 sec | 37 | |
| 94/4 min | 94/30 sec | 53/30 sec | 72/1 min | 72/4 min | 35 | |
| 94/4 min | 94/45 sec | 56/45 | 72/30 sec | 72/2 min | 30 | |
Oligonucleotide primers used for the simultaneous amplification of nuc, mecA, PVL genes of Staphylococcus aureus.
| Primer | Primer sequence (5′-3′) | Product size (bp) | Reference |
|---|---|---|---|
| GCGATTGATGGTGATACGGTI | 270 | ||
| AGCCAAGCCTTGACGAACTAAAGC | |||
| TCCAGATTACAACTTCACCAGG | 162 | ||
| CAATTCATATCTTGTAACG | |||
| ATCATTAGGTAAAATGTCTGGACATGATCA | 433 | ||
| GCATCAAGTGTATTGGATAGCAAAAGC |
Age and gender distribution of patients.
| Age | Male (%) | Female (%) |
|---|---|---|
| ≤10 | 0 (0) | 0 (0) |
| 11–20 | 0 (0) | 0 (0) |
| 21–30 | 0 (0) | 10 (20) |
| 31–40 | 1 (7) | 10 (20) |
| 41–50 | 3 (21) | 9 (18) |
| 51–60 | 10 (71) | 13 (26) |
| 61–70 | 0 (0) | 7 (14) |
| 71–80 | 0 (0) | 2 (4) |
| ≥81 | 0 (0) | 0 (0) |
Fig. 1Different resistant pattern against Ceftriaxone and Gentamicin.
Fig. 2PCR showing positive amplification of 162 bp fragments specific for mecA gene of S. aureus. Lane 1 showing 100 bp ladder. Lane 2 showing negative control S. aureus ATCC 25923. Lane 3 showing positive control.
Fig. 3PCR showing positive amplification of 162 bp fragments specific for pvl gene of S. aureus. Lane 1 showing 100 bp ladder. Lane 2 showing negative control. Lane 3 showing positive control. Lane 7 and 17 showing relatively faint band.
Fig. 4Sequence pattern (snapshot) of 4 isolates those are compared with a control sequence (Accession No. KP896298.1.
Fig. 5Amino acids multiple sequence alignment of pvl gene. The alignment was performed using ClustalW sequence alignment.
Gender distribution of patients infected with CA-MRSA and HA-MRSA.
| Sex | CA-MRSA (n = 22) | HA-MRSA (n = 16) | |
|---|---|---|---|
| Male | 6 | 5 | 0.92 |
| Female | 16 | 11 | 0.92 |
P ≤ 0.05 considered statistically significant.
Clinical samples and infections caused by CA-MRSA and HA-MRSA.
| Type of sample | CA-MRSA (n = 22) | HA-MRSA (n = 16) | |
|---|---|---|---|
| Urine | 6 | 13 | <0.005 |
| Pus | 10 | 2 | <0.005 |
| Wound swab (w/s) | 6 | 1 | <0.005 |
P ≤ 0.05 considered statistically significant.
Antibiotic resistance pattern of CA-MRSA and HA-MRSA.
| Antibiotics | Antibiotic resistance pattern | ||
|---|---|---|---|
| CA-MRSA (n = 22) Number (%) | HA-MRSA (n = 16) Number (%) | ||
| Cefoxitin | 22 | 16 | – |
| Ciprofloxacin | 10 | 10 | 0.375 |
| Chloramphenicol | 18 | 10 | 0.175 |
| Clindamycin | 04 | 10 | <0.01 |
| Oxacillin | 22 | 16 | – |
| Tetracyclin | 15 | 15 | 0.075 |
| Gentamicin | 14 | 14 | 0.100 |
| Ceftazidime | 21 | 15 | 0.925 |
| Vancomycin | 0 | 0 | – |
P ≤ 0.05 considered statistically significant.
Comparison of different methods for detection of HA-MRSA and CA-MRSA.
| Type of detection | HA-MRSA | CA-MRSA |
|---|---|---|
| Antibiogram | Good (11/16) | Poor (12/22) |
| PCR (molecular method) | Extremely good (16/16) | Extremely good (22/22) |